Cinqair (reslizumab; Teva) Drug Overview 2018 - ResearchAndMarkets.com
May. 14, 2018
DUBLIN--(BUSINESS WIRE)--May 14, 2018--The "Drug Overview: Cinqair" report has been added to ResearchAndMarkets.com's offering.
Cinqair (reslizumab; Teva) is a humanized monoclonal antibody which targets interleukin (IL)-5. IL-5 has been shown to play a key role in the maturation, growth, and chemotaxis of eosinophils, which are inflammatory white blood cells implicated in a number of allergic diseases, including asthma. Cinqair gained US and EU approvals for use in asthma in an IV formulation in March 2016 and August 2016, respectively. Teva is also developing a subcutaneous formulation of Cinqair, which is in Phase III.
Key Topics Covered:
List of Figures
Drug assessment summary of Xolair in asthma
Xolair sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Cinqair sales for asthma across the US and five major EU markets, by country, 2017-26
List of Tables
Cinqair drug profile
Cinqair pivotal Phase III data in asthma
Cinqair sales for asthma across the US and five major EU markets, by country ($m), 2017-26
For more information about this report visit https://www.researchandmarkets.com/research/fxzcsf/cinqair?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180514006203/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Asthma Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 05/14/2018 02:34 PM/DISC: 05/14/2018 02:34 PM